查看購物車
  • Simplified Chinese
  • English
  • Japanese
疫苗佐劑的全球市場：按產品類型、按 ROA、按疾病類型、按疫苗、按類型 - 預測（至 2029 年）
市場調查報告書
商品編碼
1617393

疫苗佐劑的全球市場：按產品類型、按 ROA、按疾病類型、按疫苗、按類型 - 預測（至 2029 年）

Vaccine Adjuvants Market by Product, ROA, Disease Type, Vaccine (Human, Veterinary ), Type - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 389 Pages | 訂單完成後即時交付

價格

全球疫苗佐劑市場規模預計將從2024年的7億美元成長到2029年的9.6億美元以上，複合年成長率高達6.5%。

Toll樣受體促效劑、乳劑和皂素類化合物等佐劑的創新，亞太、拉丁美洲和非洲等地區免疫項目數量的增加，以及獸用疫苗需求的不斷成長，正在推動獸用疫苗的成長。是疫苗佐劑市場的一些預期因素。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
單元 美元
部分 產品類型、佐劑類型、用途、給藥途徑、疫苗類型、疾病類型
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲

“2023年乳液型添加劑領域所佔佔有率最高。”

乳劑佐劑因其增強免疫反應的功效以及在感染疾病、癌症等各種疫苗類型中的廣泛應用而佔據壓倒性的市場佔有率。由於疫苗技術的進步以及對更有針對性和更有效的疫苗的需求不斷增加，病原體成分部分可能會以顯著的複合年成長率成長。

“到 2023 年，有機佐劑類型將主導市場。”

有機佐劑的優越性在於其在不同疫苗平台（包括 mRNA 和 DNA 疫苗）中的多功能性以及增強人用和獸用疫苗免疫反應的能力。由於安全性、功效、成本效益以及在人用和獸用疫苗中的廣泛應用等多種因素，無機佐劑預計將以顯著的複合年成長率成長。

“感染疾病領域佔據了壓倒性的佔有率。”

由於感染疾病流行不斷增加、全球免疫計畫不斷增加以及研發資金不斷增加，感染疾病細分市場佔據了市場主導地位。由於 TLR促效劑、水包油乳劑、細胞激素的採用增加以及癌症疫苗開發中向個人化疫苗的轉變，癌症細分市場可能會以強勁的複合年成長率成長。

《北美：疫苗佐劑市佔率最大》

預計北美將在 2023 年主導疫苗佐劑市場，並在預測期內繼續保持主導地位。該地區的優勢在於其先進的醫療基礎設施、強大的研發活動以及感染疾病和癌症的流行。此外，新型疫苗佐劑的強大研究和開發以及該地區主要市場參與者的存在是預計該地區市場成長的一些關鍵因素。

本報告研究和分析了全球疫苗佐劑市場，提供了包括關鍵促進因素和限制因素、競爭格局和未來趨勢等資訊。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

  • 疫苗佐劑市場概況
  • 北美疫苗佐劑市場：按產品、按國家分類（2023 年）
  • 疫苗佐劑市場佔有率：依疫苗類型分類（2024 年和 2029 年）
  • 疫苗佐劑市場：地理成長機會

第5章市場概況

  • 介紹
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 任務
  • 影響客戶業務的趨勢/干擾
  • 價格分析
    • 產品平均售價趨勢：依主要企業分類（2022-2024）
    • 產品平均售價：依地區分類（2024 年）
  • 供應鏈分析
  • 價值鏈分析
  • 生態系分析
    • 疫苗佐劑市場：原料供應商
    • 疫苗佐劑市場：產品製造商
    • 疫苗佐劑市場：最終用戶
    • 疫苗佐劑市場：監管機構
  • 技術分析
    • 主要技術
    • 互補技術
    • 鄰近技術
  • 專利分析
  • 重大會議和活動（2024-2025）
  • 監管分析
    • 監管環境
    • 監管機構、政府機構和其他組織
  • 投資金籌措場景
  • 波特五力分析
  • 主要相關利益者和採購標準
  • 貿易分析
    • 導入資料
    • 匯出資料
  • 疫苗佐劑管道資料
  • 人工智慧/生成人工智慧對疫苗佐劑市場的影響

第6章疫苗佐劑市場：依產品

  • 介紹
  • 乳劑佐劑
  • 病原體成分
  • 皂素類佐劑
  • 顆粒佐劑
  • 其他助劑

第7章疫苗佐劑市場：依佐劑類型

  • 介紹
  • 有機佐劑
  • 無機佐劑

第8章疫苗佐劑市場：依給藥途徑分類

  • 介紹
  • 肌肉
  • 皮下的
  • 其他給藥途徑

第9章疫苗佐劑市場：依疾病類型

  • 介紹
  • 感染疾病
  • 癌症
  • 其他疾病

第10章疫苗佐劑市場：依應用分類

  • 介紹
  • 研究用途
  • 商業用途

第11章疫苗佐劑市場：依疫苗類型

  • 介紹
  • 人類疫苗
  • 動物疫苗

第12章疫苗佐劑市場：按地區

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 亞太宏觀經濟展望
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 拉丁美洲
    • 拉丁美洲宏觀經濟展望
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 中東
    • 中東宏觀經濟展望
    • 海灣合作理事會國家
    • 其他中東地區
  • 非洲

第13章競爭格局

  • 概述
  • 主要參與企業的策略/優勢（2023）
  • 收益分析（2019-2023）
  • 市場佔有率分析（2023）
  • 企業評價矩陣：主要企業（2023年）
  • 公司評估矩陣：Start-Ups/中小企業（2023）
  • 公司評價及財務指標
  • 品牌/產品比較
  • 競爭場景

第14章 公司簡介

  • 主要企業
    • GSK PLC
    • SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP)
    • CRODA INTERNATIONAL PLC
    • PHIBRO ANIMAL HEALTH CORPORATION
    • SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC)
    • AGENUS INC.
    • NOVAVAX
    • AURORIUM (FORMERLY VERTELLUS)
    • DYNAVAX TECHNOLOGIES CORPORATION
    • MERCK KGAA
    • VAXINE PTY LTD.
    • HAWAII BIOTECH INC.
    • CSL LIMITED
    • OZ BIOSCIENCES
    • INVIVOGEN
  • 其他公司
    • ALLERGY THERAPEUTICS
    • EUBIOLOGICS CO., LTD.
    • PACIFIC GENETECH LIMITED
    • RIBOXX GMBH
    • CAPTIVATE PHARMACEUTICALS LLC
    • CREATIVE DIAGNOSTICS
    • LITEVAX BV
    • MUKTA INDUSTRIES
    • ONCOVIR, INC.
    • TITERMAX USA, INC.

第15章附錄

Product Code: BT 4378

The global vaccine adjuvants market is projected to surpass USD 0.96 billion in 2029 from USD 0.70 billion in 2024, with a significant CAGR of 6.5%. Innovations in adjuvants, such as toll-like receptor agonists, emulsions, and saponin-based compounds, increased immunization programs in regions like Asia-Pacific, Latin America, and Africa, and rising demand for veterinary vaccines are some of the factors projecting growth of the vaccine adjuvants market.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Product, Adjuvant Type, Application, Route of Administration, Vaccine Type, Disease Type
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The emulsion-based adjuvants segment accounted for the highest share in 2023."

On the basis of product, the vaccine adjuvant market is segmented into emulsion-based adjuvants, pathogen components, saponin-based adjuvants, particulate-based adjuvants and other products. Emulsion-based adjuvants accounted for the dominant share due to their effectiveness in enhancing immune responses and diversified applications in various vaccine types such as infectious diseases, cancer, and others. The pathogen components segment is likely to grow at a significant CAGR owing to advancements in vaccine technology and increased demand for more targeted, effective vaccines.

" Organic adjuvant type dominated the market in 2023"

The adjuvant type segment is divided into organic and inorganic adjuvants. Organic adjuvants dominated the market in 2023. The factors attributable to their dominance are their versatility in various vaccine platforms (including mRNA and DNA vaccines) and their ability to enhance the immune response in both human and veterinary vaccines. Inorganic adjuvants are anticipated to grow at a significant CAGR owing to various factors such as safety profiles, efficacy, cost-effectiveness, and broad application across both human and veterinary vaccines.

" Infectious diseases segment held dominant share"

On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and other diseases. The infectious diseases segment dominated the market owing to the increasing prevalence of infectious diseases, the rise in immunization programs across the globe, and the rise in research & development funding. The cancer segment is likely to grow at a significant CAGR owing to the increased adoption of TLR agonists, oil-in-water emulsions, and cytokines in cancer vaccine development and the shift towards personalized vaccines.

"North America: the largest share of the vaccine adjuvants market"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the vaccine adjuvants market in 2023 and is estimated to continue dominance during the forecast period. The region's dominance is driven by advanced healthcare infrastructure, strong research and development activities, and the rising prevalence of infectious diseases and cancer. Furthermore, strong research & development for novel vaccine adjuvants and the presence of key market players in the region are some of the major factors projecting the growth of the market in the region.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the vaccine adjuvants market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Tire 1 - 45%, Tire 2 - 35%, andTire 3 - 20%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

GSK Plc (UK), Seppic (France), Croda International Plc (UK), SPI Pharma (UK), Phibro Animal Health Corporation (US), Agenus Inc. (US), Dynavax Technologies Corporation (US)are some of the major players operating in the vaccine adjuvants market.

Research Coverage:

This research report categorizes the vaccine adjuvants market product (driven by advanced healthcare infrastructure, strong research and development initiatives, and high cancer prevalence), adjuvant type (organic and inorganic), disease tye (infectious diseases, cancer, and others), application (commercial & research), vaccine type (human and veterinary), route of administration ( intramuscular, subcutaneous and other route of administration) nd region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the vaccine adjuvants market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the vaccine adjuvants market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the vaccine adjuvants and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising demand for vaccines and expanding government immunization programs, technological advancements & development of novel adjuvants, increasing livestock production and rising incidence of animal diseases, increased investment in research & development, and higher number of vaccines under pipeline), restraints (cost implications of vaccine adjuvant development and side effects and toxicity of adjuvants), opportunities (personalized and combination vaccines, increased investment in R&D plant-based vaccines and growth in companion animals market) and Challenges (concerns regarding animal-sourced vaccine adjuvants ) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on upcoming technologies in vaccine adjuvants manufacturing, research and development activities, and new product launches in the vaccine adjuvants market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the vaccine adjuvants market
  • Competitive Assessment: GSK Plc (UK), Sepppic (France), Croda International Plc (UK), SPI Pharma (UK) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 MARKET ESTIMATION
    • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
    • 2.2.3 TOP-DOWN APPROACH
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 VACCINE ADJUVANTS MARKET OVERVIEW
  • 4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2023)
  • 4.3 VACCINE ADJUVANTS MARKET SHARE, BY VACCINE TYPE, 2024 VS. 2029
  • 4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising demand for vaccines and expanding government immunization programs
      • 5.2.1.2 Technological advancements and development of novel adjuvants
      • 5.2.1.3 Increasing livestock production and rising incidence of animal diseases
      • 5.2.1.4 Increased investments in research & development and high number of vaccine adjuvants under pipeline
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Cost implications of vaccine adjuvant development
      • 5.2.2.2 Side effects and toxicity of adjuvants
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Personalized and combination vaccines
      • 5.2.3.2 Increased investments in R&D of plant-based vaccines
      • 5.2.3.3 Growth in companion animals market
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Concerns regarding animal-sourced vaccine adjuvants
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.4.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2024
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • 5.7.1 VACCINE ADJUVANTS MARKET: RAW MATERIAL SUPPLIERS
    • 5.7.2 VACCINE ADJUVANTS MARKET: PRODUCT MANUFACTURERS
    • 5.7.3 VACCINE ADJUVANTS MARKET: END USERS
    • 5.7.4 VACCINE ADJUVANTS MARKET: REGULATORY BODIES
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Toll-like receptor (TLR) agonists
      • 5.8.1.2 Emulsion-based adjuvants
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
      • 5.8.2.1 Artificial intelligence (AI) and machine learning (ML)
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 Nanotechnology in vaccine delivery
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.11 REGULATORY ANALYSIS
    • 5.11.1 REGULATORY LANDSCAPE
      • 5.11.1.1 North America
        • 5.11.1.1.1 US
        • 5.11.1.1.2 Canada
      • 5.11.1.2 Europe
      • 5.11.1.3 Asia Pacific
    • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12 INVESTMENT & FUNDING SCENARIO
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 THREAT OF NEW ENTRANTS
    • 5.13.2 THREAT OF SUBSTITUTES
    • 5.13.3 BARGAINING POWER OF BUYERS
    • 5.13.4 BARGAINING POWER OF SUPPLIERS
    • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 BUYING CRITERIA FOR END USERS
  • 5.15 TRADE ANALYSIS
    • 5.15.1 IMPORT DATA
    • 5.15.2 EXPORT DATA
  • 5.16 PIPELINE DATA FOR VACCINE ADJUVANTS
  • 5.17 IMPACT OF AI/GENERATIVE AI ON VACCINE ADJUVANTS MARKET

6 VACCINE ADJUVANTS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 EMULSION ADJUVANTS
    • 6.2.1 EXTENSIVE USE OF EMULSION ADJUVANTS IN HUMAN VACCINES TO DRIVE GROWTH
  • 6.3 PATHOGEN COMPONENTS
    • 6.3.1 INCREASING NUMBER OF PROMINENT MARKET PLAYERS OFFERING BACTERIA-DERIVED ADJUVANTS TO DRIVE SEGMENTAL GROWTH
  • 6.4 SAPONIN-BASED ADJUVANTS
    • 6.4.1 INCREASING USE AND GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET GROWTH
  • 6.5 PARTICULATE-BASED ADJUVANTS
    • 6.5.1 GROWING POPULARITY OF MINERAL-BASED ADJUVANTS TO PROPEL MARKET
  • 6.6 OTHER ADJUVANTS

7 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE

  • 7.1 INTRODUCTION
  • 7.2 ORGANIC ADJUVANTS
    • 7.2.1 GROWING DEMAND FOR VACCINES WITH HIGH EFFICACY TO BOOST MARKET
  • 7.3 INORGANIC ADJUVANTS
    • 7.3.1 INCREASING USE OF INORGANIC ADJUVANTS FOR VETERINARY VACCINE DEVELOPMENT TO SUPPORT MARKET GROWTH

8 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

  • 8.1 INTRODUCTION
  • 8.2 INTRAMUSCULAR
    • 8.2.1 INTRAMUSCULAR ROUTE TO BE LARGEST AND FASTEST-GROWING MARKET SEGMENT DURING FORECAST PERIOD
  • 8.3 SUBCUTANEOUS
    • 8.3.1 WIDESPREAD USE OF SUBCUTANEOUS ROUTE OF ADMINISTRATION TO BOOST MARKET
  • 8.4 OTHER ROUTES OF ADMINISTRATION

9 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE

  • 9.1 INTRODUCTION
  • 9.2 INFECTIOUS DISEASES
    • 9.2.1 INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
  • 9.3 CANCER
    • 9.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH
  • 9.4 OTHER DISEASES

10 VACCINE ADJUVANTS MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 RESEARCH APPLICATIONS
    • 10.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET
  • 10.3 COMMERCIAL APPLICATIONS
    • 10.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH

11 VACCINE ADJUVANTS MARKET, BY VACCINE TYPE

  • 11.1 INTRODUCTION
  • 11.2 HUMAN VACCINES
    • 11.2.1 INFECTIOUS DISEASES
      • 11.2.1.1 Rising prevalence of infectious diseases to drive market growth
    • 11.2.2 THERAPEUTIC
      • 11.2.2.1 Rising investments in development of therapeutic vaccines to boost market
  • 11.3 VETERINARY VACCINES
    • 11.3.1 COMPANION ANIMALS
      • 11.3.1.1 Increasing pet ownership and rising focus on pet health and wellness to play key role in driving market growth
    • 11.3.2 LIVESTOCK ANIMALS
      • 11.3.2.1 Increasing demand for high-quality meat, dairy, and other animal products to aid growth
    • 11.3.3 OTHER ANIMALS

12 VACCINE ADJUVANTS MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 US to dominate North American market during forecast period
    • 12.2.3 CANADA
      • 12.2.3.1 Increasing government funding for vaccine research to drive market growth in Canada
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 Increasing investments by various key players and growing funding from government organizations to drive market
    • 12.3.3 UK
      • 12.3.3.1 Rising investments in vaccine development to boost market growth
    • 12.3.4 FRANCE
      • 12.3.4.1 Focus on new vaccine development to drive market growth
    • 12.3.5 ITALY
      • 12.3.5.1 Government initiatives for vaccine development to boost market growth
    • 12.3.6 SPAIN
      • 12.3.6.1 Increasing investments in vaccine development by government and private organizations to support market growth in Spain
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China
    • 12.4.3 JAPAN
      • 12.4.3.1 Government initiatives for vaccines to boost market
    • 12.4.4 INDIA
      • 12.4.4.1 Growth of biotechnology sector and development of new vaccines to support market growth in India
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Strategic collaborations to expand both human and veterinary vaccine sectors in South Korea
    • 12.4.6 AUSTRALIA
      • 12.4.6.1 Government support and strategic alliances to drive market
    • 12.4.7 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Robust healthcare infrastructure and thriving livestock industry to support market growth
    • 12.5.3 MEXICO
      • 12.5.3.1 Government commitment to immunization programs to fuel growth
    • 12.5.4 ARGENTINA
      • 12.5.4.1 Growing pharmaceutical sector to drive growth in Argentina
    • 12.5.5 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST
    • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Saudi Arabia
        • 12.6.2.1.1 Strategic emphasis on advancing vaccine development for both human and veterinary applications to fuel growth
      • 12.6.2.2 United Arab Emirates (UAE)
        • 12.6.2.2.1 Increasing focus on developing cutting-edge vaccine technologies to contribute to market growth
      • 12.6.2.3 Rest of GCC countries
    • 12.6.3 REST OF MIDDLE EAST
  • 12.7 AFRICA
    • 12.7.1 INCREASING INVESTMENTS IN VACCINE PRODUCTION FACILITIES TO SUPPORT MARKET GROWTH
    • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINE ADJUVANTS MARKET
  • 13.3 REVENUE ANALYSIS, 2019-2023
  • 13.4 MARKET SHARE ANALYSIS, 2023
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 13.5.5.1 Company footprint
      • 13.5.5.2 Product footprint
      • 13.5.5.3 Application footprint
      • 13.5.5.4 Region footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 13.7 COMPANY VALUATION & FINANCIAL METRICS
    • 13.7.1 FINANCIAL METRICS
    • 13.7.2 COMPANY VALUATION
  • 13.8 BRAND/PRODUCT COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES & APPROVALS
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 GSK PLC
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Deals
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Key strengths
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses & competitive threats
    • 14.1.2 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP)
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses & competitive threats
    • 14.1.3 CRODA INTERNATIONAL PLC
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Deals
        • 14.1.3.3.2 Expansions
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Key strengths
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses & competitive threats
    • 14.1.4 PHIBRO ANIMAL HEALTH CORPORATION
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products offered
      • 14.1.4.3 MnM view
        • 14.1.4.3.1 Key strengths
        • 14.1.4.3.2 Strategic choices
        • 14.1.4.3.3 Weaknesses & competitive threats
    • 14.1.5 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC)
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products offered
      • 14.1.5.3 MnM view
        • 14.1.5.3.1 Key strengths
        • 14.1.5.3.2 Strategic choices
        • 14.1.5.3.3 Weaknesses & competitive threats
    • 14.1.6 AGENUS INC.
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Deals
    • 14.1.7 NOVAVAX
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products offered
    • 14.1.8 AURORIUM (FORMERLY VERTELLUS)
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Deals
    • 14.1.9 DYNAVAX TECHNOLOGIES CORPORATION
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Deals
    • 14.1.10 MERCK KGAA
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products offered
    • 14.1.11 VAXINE PTY LTD.
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products offered
    • 14.1.12 HAWAII BIOTECH INC.
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products offered
    • 14.1.13 CSL LIMITED
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products offered
    • 14.1.14 OZ BIOSCIENCES
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products offered
    • 14.1.15 INVIVOGEN
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products offered
  • 14.2 OTHER PLAYERS
    • 14.2.1 ALLERGY THERAPEUTICS
    • 14.2.2 EUBIOLOGICS CO., LTD.
    • 14.2.3 PACIFIC GENETECH LIMITED
    • 14.2.4 RIBOXX GMBH
    • 14.2.5 CAPTIVATE PHARMACEUTICALS LLC
    • 14.2.6 CREATIVE DIAGNOSTICS
    • 14.2.7 LITEVAX B.V.
    • 14.2.8 MUKTA INDUSTRIES
    • 14.2.9 ONCOVIR, INC.
    • 14.2.10 TITERMAX USA, INC.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 VACCINE ADJUVANTS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 3 VACCINE ADJUVANTS MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 4 GLOBAL DIPHTHERIA TETANUS TOXOID AND PERTUSSIS (DTP) VACCINATION COVERAGE, 2019-2023
  • TABLE 5 GLOBAL BACILLUS CALMETTE-GUERIN (BCG) VACCINATION COVERAGE, 2019-2023
  • TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
  • TABLE 7 AVERAGE SELLING PRICE OF PRODUCT, BY REGION, 2024
  • TABLE 8 VACCINE ADJUVANTS MARKET: RAW MATERIAL SUPPLIERS
  • TABLE 9 VACCINE ADJUVANTS MARKET: PRODUCT MANUFACTURERS
  • TABLE 10 VACCINE ADJUVANTS MARKET: END USERS
  • TABLE 11 VACCINE ADJUVANTS MARKET: REGULATORY BODIES
  • TABLE 12 KEY PATENTS IN VACCINE ADJUVANTS MARKET
  • TABLE 13 VACCINE ADJUVANTS MARKET: KEY CONFERENCES & EVENTS, 2024-2025
  • TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 VACCINE ADJUVANTS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 20 KEY BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS, BY END USER
  • TABLE 21 IMPORT DATA FOR VACCINE ADJUVANTS
  • TABLE 22 EXPORT DATA FOR VACCINE ADJUVANTS
  • TABLE 23 PIPELINE STUDIES FOR VACCINE ADJUVANTS, PHASE 3 AND PHASE 2|PHASE3
  • TABLE 24 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 25 EMULSION ADJUVANTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 26 NORTH AMERICA: EMULSION ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 27 EUROPE: EMULSION ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: EMULSION ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 LATIN AMERICA: EMULSION ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 MIDDLE EAST: EMULSION ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 GCC COUNTRIES: EMULSION ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 32 PATHOGEN COMPONENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 33 NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 LATIN AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 MIDDLE EAST: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 GCC COUNTRIES: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 SAPONIN-BASED ADJUVANTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 40 NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 LATIN AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 MIDDLE EAST: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 GCC COUNTRIES: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 PARTICULATE-BASED ADJUVANTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 47 NORTH AMERICA: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 EUROPE: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 LATIN AMERICA: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 MIDDLE EAST: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 GCC COUNTRIES: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 OTHER ADJUVANTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 54 NORTH AMERICA: OTHER ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 EUROPE: OTHER ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: OTHER ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 LATIN AMERICA: OTHER ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 MIDDLE EAST: OTHER ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 GCC COUNTRIES: OTHER ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 61 ORGANIC VACCINE ADJUVANTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 62 NORTH AMERICA: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 EUROPE: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 LATIN AMERICA: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 MIDDLE EAST: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 GCC COUNTRIES: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 INORGANIC VACCINE ADJUVANTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 EUROPE: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 LATIN AMERICA: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 MIDDLE EAST: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 GCC COUNTRIES: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 76 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION
  • TABLE 77 VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 82 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION
  • TABLE 85 VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 90 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 91 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 92 VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 97 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 98 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 99 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 100 GLOBAL IMMUNIZATION COVERAGE, BY VACCINE, 2020-2023 (%)
  • TABLE 101 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 102 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 103 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 105 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 106 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 107 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 108 VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 109 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 110 EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 112 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 113 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 114 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 115 VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 116 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 119 LATIN AMERICA: VACCINE ADJUVANTS MARKET OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 120 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 121 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 122 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 123 VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 124 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 127 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 128 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 129 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 130 VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 131 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 134 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 135 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 136 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 138 VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 139 VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 140 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 141 EUROPE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 142 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 143 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 144 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 145 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 146 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 147 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 148 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 150 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 151 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 152 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 153 VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 154 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 155 EUROPE: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 157 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 158 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 159 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 160 VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 161 VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 162 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 163 EUROPE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 164 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 165 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 166 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 167 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 168 VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 169 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 170 EUROPE: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 171 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 172 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 173 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 174 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 175 VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 176 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 177 EUROPE: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 178 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 179 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 180 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 181 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 182 VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 183 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 184 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 186 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 187 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 188 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 189 VACCINE ADJUVANTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 190 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 191 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 192 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 193 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 194 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 195 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 196 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 197 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 198 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 199 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 200 US: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 201 US: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 202 US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 203 US: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 204 US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 205 US: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 206 US: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 207 US: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 208 CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 209 CANADA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 210 CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 211 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 212 CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 213 CANADA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 214 CANADA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 215 CANADA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 216 EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 217 EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 218 EUROPE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 219 EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 220 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 221 EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 222 EUROPE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 223 EUROPE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 224 EUROPE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 225 EUROPE: KEY MACROINDICATORS
  • TABLE 226 GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 227 GERMANY: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 228 GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 229 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 230 GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 231 GERMANY: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 232 GERMANY: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 233 GERMANY: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 234 UK: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 235 UK: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 236 UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 237 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 238 UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 239 UK: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 240 UK: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 241 UK: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 242 FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 243 FRANCE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 244 FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 245 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 246 FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 247 FRANCE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 248 FRANCE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 249 FRANCE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 250 ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 251 ITALY: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 252 ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 253 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 254 ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 255 ITALY: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 256 ITALY: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 257 ITALY: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 258 SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 259 SPAIN: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 260 SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 261 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 262 SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 263 SPAIN: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 264 SPAIN: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 265 SPAIN: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 266 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 267 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 268 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 269 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 270 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 271 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 272 REST OF EUROPE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 273 REST OF EUROPE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 274 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 275 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 276 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 277 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 278 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 279 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 280 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 281 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 282 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 283 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 284 CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 285 CHINA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 286 CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 287 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 288 CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 289 CHINA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 290 CHINA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 291 CHINA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 292 JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 293 JAPAN: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 294 JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 295 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 296 JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 297 JAPAN: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 298 JAPAN: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 299 JAPAN: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 300 INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 301 INDIA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 302 INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 303 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 304 INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 305 INDIA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 306 INDIA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 307 INDIA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 308 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 309 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 310 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 311 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 312 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 313 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 314 SOUTH KOREA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 315 SOUTH KOREA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 316 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 317 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 318 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 319 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 320 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 321 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 322 AUSTRALIA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 323 AUSTRALIA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 324 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 325 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 326 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 327 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 328 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 329 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 330 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 331 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 332 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 333 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 334 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 335 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 336 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 337 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 338 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 339 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 340 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 341 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 342 BRAZIL: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 343 BRAZIL: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 344 BRAZIL: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 345 BRAZIL: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 346 BRAZIL: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 347 BRAZIL: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 348 BRAZIL: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 349 BRAZIL: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 350 MEXICO: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 351 MEXICO: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 352 MEXICO: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 353 MEXICO: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 354 MEXICO: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 355 MEXICO: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 356 MEXICO: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 357 MEXICO: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 358 ARGENTINA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 359 ARGENTINA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 360 ARGENTINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 361 ARGENTINA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 362 ARGENTINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 363 ARGENTINA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 364 ARGENTINA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 365 ARGENTINA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 366 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 367 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 368 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 369 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 370 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 371 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 372 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 373 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 374 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 375 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 376 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 377 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 378 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 379 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 380 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 381 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 382 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 383 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 384 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 385 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 386 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 387 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 388 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 389 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 390 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 391 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 392 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 393 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 394 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 395 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 396 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 397 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 398 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 399 SAUDI ARABIA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 400 SAUDI ARABIA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 401 UAE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 402 UAE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 403 UAE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 404 UAE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 405 UAE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 406 UAE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 407 UAE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 408 UAE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 409 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 410 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 411 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 412 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 413 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 414 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 415 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 416 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 417 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 418 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 419 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 420 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 421 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 422 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 423 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 424 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 425 AFRICA: KEY MACROINDICATORS
  • TABLE 426 AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 427 AFRICA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022-2029 (USD MILLION)
  • TABLE 428 AFRICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 429 AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 430 AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022-2029 (USD MILLION)
  • TABLE 431 AFRICA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022-2029 (USD MILLION)
  • TABLE 432 AFRICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 433 AFRICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 434 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINE ADJUVANTS MARKET
  • TABLE 435 VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION
  • TABLE 436 VACCINE ADJUVANTS MARKET: PRODUCT FOOTPRINT
  • TABLE 437 VACCINE ADJUVANTS MARKET: APPLICATION FOOTPRINT
  • TABLE 438 VACCINE ADJUVANTS MARKET: REGION FOOTPRINT
  • TABLE 439 VACCINE ADJUVANTS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 440 VACCINE ADJUVANTS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 441 VACCINE ADJUVANTS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 442 VACCINE ADJUVANTS MARKET: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 443 VACCINE ADJUVANTS MARKET: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 444 GSK PLC: COMPANY OVERVIEW
  • TABLE 445 GSK PLC: PRODUCTS OFFERED
  • TABLE 446 GSK PLC: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 447 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): COMPANY OVERVIEW
  • TABLE 448 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): PRODUCTS OFFERED
  • TABLE 449 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 450 CRODA INTERNATIONAL PLC: COMPANY OVERVIEW
  • TABLE 451 CRODA INTERNATIONAL PLC: PRODUCTS OFFERED
  • TABLE 452 CRODA INTERNATIONAL PLC: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 453 CRODA INTERNATIONAL PLC: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 454 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY OVERVIEW
  • TABLE 455 PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED
  • TABLE 456 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC): COMPANY OVERVIEW
  • TABLE 457 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC): PRODUCTS OFFERED
  • TABLE 458 AGENUS INC.: COMPANY OVERVIEW
  • TABLE 459 AGENUS INC.: PRODUCTS OFFERED
  • TABLE 460 AGENUS INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 461 NOVAVAX: COMPANY OVERVIEW
  • TABLE 462 NOVAVAX: PRODUCTS OFFERED
  • TABLE 463 AURORIUM (FORMERLY VERTELLUS): COMPANY OVERVIEW
  • TABLE 464 AURORIUM (FORMERLY VERTELLUS): PRODUCTS OFFERED
  • TABLE 465 AURORIUM (FORMERLY VERTELLUS): DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 466 DYNAVAX TECHNOLOGIES CORPORATION: COMPANY OVERVIEW
  • TABLE 467 DYNAVAX TECHNOLOGIES CORPORATION: PRODUCTS OFFERED
  • TABLE 468 DYNAVAX TECHNOLOGIES CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 469 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 470 MERK KGAA: PRODUCTS OFFERED
  • TABLE 471 VAXINE PTY LTD.: COMPANY OVERVIEW
  • TABLE 472 VAXINE PTY LTD.: PRODUCTS OFFERED
  • TABLE 473 HAWAII BIOTECH INC.: COMPANY OVERVIEW
  • TABLE 474 HAWAII BIOTECH INC.: PRODUCTS OFFERED
  • TABLE 475 CSL LIMITED: COMPANY OVERVIEW
  • TABLE 476 CSL LIMITED: PRODUCTS OFFERED
  • TABLE 477 OZ BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 478 OZ BIOSCIENCES: PRODUCTS OFFERED
  • TABLE 479 INVIVOGEN: COMPANY OVERVIEW
  • TABLE 480 INVIVOGEN: PRODUCTS OFFERED
  • TABLE 481 ALLERGY THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 482 EUBIOLOGICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 483 PACIFIC GENETECH LIMITED: COMPANY OVERVIEW
  • TABLE 484 RIBOXX GMBH: COMPANY OVERVIEW
  • TABLE 485 CAPTIVATE PHARMACEUTICALS LLC: COMPANY OVERVIEW
  • TABLE 486 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 487 LITEVAX B.V.: COMPANY OVERVIEW
  • TABLE 488 MUKTA INDUSTRIES: COMPANY OVERVIEW
  • TABLE 489 ONCOVIR, INC.: COMPANY OVERVIEW
  • TABLE 490 TITERMAX USA, INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 VACCINE ADJUVANTS MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 VACCINE ADJUVANTS MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 4 VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 5 GLOBAL MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF GSK PLC: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 VACCINE ADJUVANTS MARKET: CAGR PROJECTIONS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET
  • FIGURE 16 ADVANCEMENTS IN VACCINE ADJUVANTS AND RISING DEMAND FOR BIO-BASED PRODUCTS TO DRIVE MARKET GROWTH
  • FIGURE 17 ADJUVANT EMULSIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 18 HUMAN VACCINES TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 19 CHINA PROJECTED TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 20 VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES IN VACCINE ADJUVANTS MARKET
  • FIGURE 22 VACCINE ADJUVANTS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 23 VACCINE ADJUVANTS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 VACCINE ADJUVANTS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 25 NUMBER OF PATENTS APPLICATIONS/GRANTED, 2014-2024
  • FIGURE 26 VACCINE ADJUVANTS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINE ADJUVANT PRODUCTS
  • FIGURE 28 KEY BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS AMONG END USERS
  • FIGURE 29 VACCINE ADJUVANTS PIPELINE, BY PHASE
  • FIGURE 30 VACCINE ADJUVANTS MARKET: IMPACT OF AI
  • FIGURE 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT
  • FIGURE 32 ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT
  • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET, 2019-2023
  • FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET (2023)
  • FIGURE 35 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 36 VACCINE ADJUVANTS MARKET: COMPANY FOOTPRINT
  • FIGURE 37 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 38 EV/EBITDA OF KEY VENDORS
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 40 VACCINE ADJUVANTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 41 GSK PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 42 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): COMPANY SNAPSHOT (2023)
  • FIGURE 43 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 44 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 45 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC): COMPANY SNAPSHOT (2023)
  • FIGURE 46 AGENUS INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 47 NOVAVAX: COMPANY SNAPSHOT (2023)
  • FIGURE 48 DYNAVAX TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 49 MERCK KGAA: COMPANY SNAPSHOT (2023)
  • FIGURE 50 CSL LIMITED: COMPANY SNAPSHOT (2023)